Cargando…
Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
BACKGROUND/AIMS: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960981/ https://www.ncbi.nlm.nih.gov/pubmed/32616682 http://dx.doi.org/10.5009/gnl19387 |
_version_ | 1783665157613813760 |
---|---|
author | Chung, Jung Wha Choi, Hwa Young Ki, Moran Jang, Eun Sun Jeong, Sook-Hyang |
author_facet | Chung, Jung Wha Choi, Hwa Young Ki, Moran Jang, Eun Sun Jeong, Sook-Hyang |
author_sort | Chung, Jung Wha |
collection | PubMed |
description | BACKGROUND/AIMS: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to investigate the detailed profiles of comorbidities and comedication among Korean CHC patients. METHODS: All adult patients (≥18 years old) with a primary diagnostic code of CHC in 2013 were selected from the National Health Insurance claims database. For each patient, all ICD-10 codes listed as primary or secondary diagnoses and all prescribed medications were collected. RESULTS: Among 47,104 CHC patients (median age, 57 years; male, 49.3%), 84.8% had at least one comorbidity for a mean number of 2.4, which increased with age. The most prevalent comorbidities were hypertension, esophagitis, dyslipidemia, diabetes mellitus, and peptic ulcer. Overall, 96.8% of the patients took at least one prescribed medication, with a mean of 8.1 medications/year, and the three most common drug types were analgesics, gastrointestinal agents, and antibacterials. Use of at least one drug with a DDI risk category of “contraindicated medication” or “required dose-reduction/additional monitoring” was observed in 97% of the overall patients. The proportion of prescribed medications that were contraindicated with DAAs varied from 2.0% to 38.9% depending on the hepatitis C virus regimen. CONCLUSIONS: The majority of CHC patients had comorbidities; almost all patients took multiple prescribed medications, the number of which increased with age, and significant DDI risk was present in 97% of this Korean patient cohort. Comorbidities and comedication profiles should be considered during DAA therapy. |
format | Online Article Text |
id | pubmed-7960981 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Editorial Office of Gut and Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-79609812021-03-24 Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study Chung, Jung Wha Choi, Hwa Young Ki, Moran Jang, Eun Sun Jeong, Sook-Hyang Gut Liver Original Article BACKGROUND/AIMS: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to investigate the detailed profiles of comorbidities and comedication among Korean CHC patients. METHODS: All adult patients (≥18 years old) with a primary diagnostic code of CHC in 2013 were selected from the National Health Insurance claims database. For each patient, all ICD-10 codes listed as primary or secondary diagnoses and all prescribed medications were collected. RESULTS: Among 47,104 CHC patients (median age, 57 years; male, 49.3%), 84.8% had at least one comorbidity for a mean number of 2.4, which increased with age. The most prevalent comorbidities were hypertension, esophagitis, dyslipidemia, diabetes mellitus, and peptic ulcer. Overall, 96.8% of the patients took at least one prescribed medication, with a mean of 8.1 medications/year, and the three most common drug types were analgesics, gastrointestinal agents, and antibacterials. Use of at least one drug with a DDI risk category of “contraindicated medication” or “required dose-reduction/additional monitoring” was observed in 97% of the overall patients. The proportion of prescribed medications that were contraindicated with DAAs varied from 2.0% to 38.9% depending on the hepatitis C virus regimen. CONCLUSIONS: The majority of CHC patients had comorbidities; almost all patients took multiple prescribed medications, the number of which increased with age, and significant DDI risk was present in 97% of this Korean patient cohort. Comorbidities and comedication profiles should be considered during DAA therapy. Editorial Office of Gut and Liver 2021-03-15 2020-07-06 /pmc/articles/PMC7960981/ /pubmed/32616682 http://dx.doi.org/10.5009/gnl19387 Text en Copyright © Gut and Liver. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Chung, Jung Wha Choi, Hwa Young Ki, Moran Jang, Eun Sun Jeong, Sook-Hyang Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study |
title | Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study |
title_full | Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study |
title_fullStr | Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study |
title_full_unstemmed | Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study |
title_short | Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study |
title_sort | comorbidities and prescribed medications in korean patients with chronic hepatitis c: a nationwide, population-based study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960981/ https://www.ncbi.nlm.nih.gov/pubmed/32616682 http://dx.doi.org/10.5009/gnl19387 |
work_keys_str_mv | AT chungjungwha comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy AT choihwayoung comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy AT kimoran comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy AT jangeunsun comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy AT jeongsookhyang comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy |